chartexchange

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

GlobeNewswire Inc. | Oct 12, 2026 4:01 PM EDT

– Trial did not meet the primary endpoint of annualized rate of FVC decline –

Read original article